Leerink says there's potentially still a chance of an eventual sale of Allscripts (MDRX -16%),...

|About: Allscripts Healthcare Solut... (MDRX)|By:, SA News Editor

Leerink says there's potentially still a chance of an eventual sale of Allscripts (MDRX -16%), despite yesterday's statement by the company regarding the conclusion of its strategic review process and decision not to put itself up for sale. It probably won't occur in the near term, however, so consequently the firm predicts the stock will continue to face significant pressure. It reduces its target range to $8 - $9 from $12 - $14.